Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00021164 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating Patients With Metastatic Cancer
A Phase 2 study of Unspecified Adult Solid Tumor, Protocol Specific and Melanoma (Skin), sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Study location
NCT00021164: Completed Phase 2 study of Unspecified Adult Solid Tumor, Protocol Specific and Melanoma (Skin), sponsored by National Cancer Institute (NCI).
NCT00021164 is a Phase 2 study of Unspecified Adult Solid Tumor, Protocol Specific and Melanoma (Skin) that has completed, run by National Cancer Institute (NCI). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00021164, a Phase 2 study of Unspecified Adult Solid Tumor, Protocol Specific and Melanoma (Skin), has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Vaccines made from a peptide may make the body build an immune response and kill tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy in treating patients who have metastatic cancer.
Conditions Studied
Interventions
- BIOLOGICAL aldesleukin
- BIOLOGICAL incomplete Freund's adjuvant
- BIOLOGICAL telomerase: 540-548 peptide vaccine
Study Locations (1)
Maryland
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support - Bethesda
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-05 |
| Est. Completion | 2004-05 |
| Phase | Phase 2 |
What the finished NCT00021164 record still lists
NCT00021164 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 2 conditions, with Unspecified Adult Solid Tumor, Protocol Specific appearing as the primary indexed condition, and to 3 interventions - of which aldesleukin is the first listed.
NCT00021164 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00021164 about?
NCT00021164 is a clinical study titled "Vaccine Therapy in Treating Patients With Metastatic Cancer". RATIONALE: Vaccines made from a peptide may make the body build an immune response and kill tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy in treating patients who have metastatic cancer.
What is the current status of trial NCT00021164?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-05. Estimated completion is 2004-05.
What conditions does trial NCT00021164 study?
This clinical trial studies the following conditions: Unspecified Adult Solid Tumor, Protocol Specific, Melanoma (Skin).
What interventions are being tested in trial NCT00021164?
The interventions under investigation include: aldesleukin (BIOLOGICAL), incomplete Freund's adjuvant (BIOLOGICAL), telomerase: 540-548 peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00021164?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00021164 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unspecified Adult Solid Tumor, Protocol Specific
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
COMPLETED · Phase 2
-
Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy
COMPLETED · Phase 2
-
S0916, MLN1202 in Treating Patients With Bone Metastases
COMPLETED · Phase 2
-
Stereotactic Body Radiation Therapy and Vertebroplasty in Treating Patients With Localized Spinal Metastasis
COMPLETED · Phase 2
-
Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors
COMPLETED · Phase 2
-
Docetaxel in Treating Patients With Solid Tumors
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia